This cell type-specific action of Oxy210 could provide a safety feature since a generalized inhibition of TGF-β signaling using neutralizing antibodies to TGF-β or genetic manipulation resulted in inflammatory adverse effects in vivo, in animal models of atherosclerosis and diabetic kidney disease, presumably through interfering with the anti-inflammatory effects of TGF-β [76,85,86]. The gene discussed is TGFB1; the disease is diabetic kidney disease.